Cartography Biosciences Announces Strategic Investment From Samsung Ventures to Advance Oncology Pipeline Posted on May 6, 2026July 29, 2026 by Logan Wisniewski
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise Posted on April 9, 2026June 29, 2026 by Logan Wisniewski
Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer Posted on February 24, 2026June 29, 2026 by Logan Wisniewski
Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens Posted on January 6, 2026June 29, 2026 by Logan Wisniewski
Cartography Receives FDA Investigational New Drug (IND) Approval and Fast Track Designation for Lead Program CBI-1214 for Colorectal Cancer Posted on December 18, 2025June 29, 2026 by Logan Wisniewski
Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic Posted on October 2, 2025July 29, 2026 by Logan Wisniewski
Cartography Names Dirk Nagorsen, M.D., as Chief Medical Officer in Expansion of Its Clinical Team Posted on September 3, 2025June 29, 2026 by Logan Wisniewski
Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors Posted on October 29, 2024June 29, 2026 by Logan Wisniewski
Cartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies Against Novel Targets and Target Pairs Posted on May 28, 2024June 29, 2026 by Logan Wisniewski
Cartography Biosciences Expands Leadership Team with Appointment of Dan Rock, Ph.D., as Chief Scientific Officer to Advance Novel Oncology Programs into Clinic Posted on February 7, 2024June 29, 2026 by Logan Wisniewski
